HALIFAX, Dec. 30 /CNW/ - MedMira Inc., ("MedMira") (TSX Venture: MIR,
NASDAQ: MMIRF), a developer and marketer of rapid diagnostic technology
and solutions, today announced its financial results for the three
month period ending October 31, 2010. Product sales in the first
quarter were $176 thousand, compared to $376 thousand in the same
quarter last year. The net loss for the quarter was $1.1 million or
$0.005 per share compared with a net loss of $1.1 million or $0.007 per
share in the same period last year. Overall gross margin for the
quarter was 48%, compared to 58% last year. Internal and general
operating expense was $536 thousand compared to $740 thousand for the
same period last year.
"The first quarter was slower than expected for MedMira due to the
longer sales cycle our strategic business development partners are
experiencing in international markets. In the multi-layer agreements
we and our business partners are pursuing in markets such as Africa,
South East Asia, and Latin America, the sales cycle, negotiations on
terms and conditions, and so on are extensive and complex," said Hermes
Chan, CEO, MedMira Inc. "We are working towards bringing the right
balance of higher margin orders along with large volume deals from both
the developed and developing regions of the world to MedMira. We
believe that this mix of customers will provide the Company with the
best long term growth strategy."
MedMira is a leading developer and manufacturer of flow-through rapid
diagnostics and technologies. The Company's tests provide hospitals,
labs, clinics and individuals with reliable, rapid diagnosis for
infectious diseases in minutes. MedMira diagnostics are sold under the
Reveal®, MiraWell®, MiraCare™ and Multiplo™ brands in global markets.
MedMira's rapid HIV test is the only one in the world to achieve
regulatory approvals in Canada, the United States, China and the
European Union. MedMira's corporate offices and manufacturing
facilities are located in Halifax, Nova Scotia, Canada. For more
information visit MedMira's website at www.medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the company's current expectation
regarding future events. Actual events could materially differ from
those projected herein and depend on a number of factors including, but
not limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this statement.
SOURCE MedMira Inc.
For further information: For further information: